Literature DB >> 15863897

Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients.

Masato Taguchi1, Takashi Nozawa, Akihiko Igawa, Hiroshi Inoue, Chihiro Takesono, Katsutoshi Tahara, Yukiya Hashimoto.   

Abstract

The nonlinear mixed effects model (NONMEM) was used to analyze the pharmacokinetics of routinely administered bisoprolol in middle-aged and elderly Japanese patients. The subjects consisted of 29 males and 11 females with a mean age of 63.5+/-10.1. Data on the plasma concentration of bisoprolol from 94 blood samples obtained at steady-state following repetitive oral administration were analyzed using the NONMEM program, where a one-compartment model with repetitive bolus dosing was parameterized in terms of oral clearance (CL/F) and apparent volume of distribution (V/F). Individual CL/F values were correlated with body weight (WT) and creatinine clearance (CLcr). The relation between CLcr and the CL/F of bisoprolol was not altered by the CYP2D6 and CYP2C19 genotypes, gender, or age. The mean CL/F value estimated with NONMEM was 0.0612.WT+1.15.CLcr (l/h), and the mean V/F value was 2.61.WT (l). The residual interindividual variability of CL/F and V/F were 22.0% and 12.6%, respectively. The pharmacokinetic variability of bisoprolol is small even in routinely treated Japanese patients, provided that both body weight and renal function are taken into account for the prediction of oral clearance of the drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863897     DOI: 10.1248/bpb.28.876

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Cardiogenic shock induced by bisoprolol in a patient with CYP2D6 variant. A case report.

Authors:  Masafumi Nakayama; Koichi Fuse; Masahito Sato; Masaaki Okabe; Yasushi Komatsu; Akira Yamashina; Yoshifusa Aizawa
Journal:  J Cardiol Cases       Date:  2015-01-19

2.  Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.

Authors:  Valentina N Nikolic; Slobodan M Jankovic; Marina Deljanin-Ilic; Sanja S Stojanovic; Miroslav Lj Nikolic; Slavoljub Zivanovic; Dragana Stokanovic; Tatjana Jevtovic-Stoimenov; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

3.  Bisoprolol responses (PK/PD) in hypertensive patients: A cytochrome P450 (CYP) 2D6 targeted polymorphism study.

Authors:  Huda Mohammed Alkreathy; Khlood Mohammed Eid Alsayyid; Jumana Y Alaama; Kamal Al Ghalayini; Shahid Karim; Ahmed Esmat; Zoheir A Damanhouri
Journal:  Saudi J Biol Sci       Date:  2020-06-20       Impact factor: 4.219

4.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

5.  Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.

Authors:  Yoshiaki Kubota; Kuniya Asai; Erito Furuse; Shunichi Nakamura; Koji Murai; Yayoi Tetsuou Tsukada; Wataru Shimizu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-05

6.  Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol.

Authors:  Vanessa Fontana; Richard Myles Turner; Ben Francis; Peng Yin; Benno Pütz; Timo P Hiltunen; Sanni Ruotsalainen; Kimmo K Kontula; Bertam Müller-Myhsok; Munir Pirmohamed
Journal:  Pharmgenomics Pers Med       Date:  2022-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.